Role of Platelet Parameters on Neovascular Glaucoma: A Retrospective Case-Control Study in China

Shengjie Li¹, Wenjun Cao¹,²*, Xinghuai Sun²,³,⁴,⁵*

¹ Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, China, ² Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College, Fudan University, China, ³ State Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Fudan University, Shanghai, China, ⁴ Key Laboratory of Myopia, Ministry of Health (Fudan University), Shanghai, China, ⁵ Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University), Shanghai, China

* wgkjyk@aliyun.com (WC); xhsun@shmu.edu.cn (XS)

Abstract

Purpose

Retinal vein occlusion (RVO) and diabetic retinopathy (DR) are two major sight-threatening diseases which may lead to neovascular glaucoma (NVG). The aim of this study was to explore the association between platelet parameters and NVG.

Methods

A total of 185 subjects were enrolled for the study from January, 2012 to December, 2015 at the Eye-ENT Hospital of Fudan University. Patients include those with NVG secondary to RVO (RVO group, n = 38), patients with NVG secondary to DR (DR group, n = 47), diabetics mellitus without retinopathy (DM group, n = 52), and healthy individuals (control group, n = 48). A complete ophthalmological examination including visual field examination, A-scan ultrasound, Fundus photography, and measurement of platelet parameters were performed for NVG subjects.

Results

There was no statistical difference in the mean age and gender among the RVO, DR, and control groups (p>0.05). The mean level of platelet distribution width (PDW) was higher (p<0.001) in the RVO group (15.16±2.13fl) and DR group (16.17±1.66fl) when compared with the control group (13.77±2.99fl). The mean plateletcrit (PCT) value of the RVO group (0.229±0.063%) was also higher (p = 0.049) than the control group (0.199±0.045). In the DR group, mean platelet volume (MPV) value (10.72±1.57fl) was significantly higher (p = 0.002) than the control group (9.75±0.89fl). A similar trend was observed when platelet parameters were compared among the 3 groups with respect to age. The mean level of PDW was significantly higher (p<0.001) in the DR group (16.17±1.66fl) compared with the DM group (13.80±3.32fl). Stepwise multiple logistic regression analysis revealed that PDW (OR = 1.44, 95%
CI = 1.149–1.805, \( p = 0.002 \) and MPV (OR = 1.503, 95%CI = 1.031–2.192, \( p = 0.034 \)) were associated with the DR group, PDW (OR = 1.207, 95%CI = 1.010–1.443, \( p = 0.039 \)) and PCT (OR = 1.663, 95%CI = 1.870–2.654, \( p = 0.036 \)) were associated with the RVO group.

**Conclusion**

Our results suggest that increased PDW and MPV are associated with the NVG secondary to DR group, elevated PDW and PCT are associated with the RVO group. It indicates that platelets might be an important factor in the onset and/or development of NVG.

**Introduction**

Neovascular glaucoma (NVG) is a frequent complication associated with ischaemic retinopathies such as retinal vein occlusion (RVO) and diabetic retinopathy (DR). The disease process is characteristically refractory, difficult to treat and often results in vision loss [1–3]. The exact mechanism by which neovascularization and vision loss is inflicted on patients with RVO and DR remains unknown, but the three factors (stasis, vessel damage and hypercoagulability) involved in thrombogenesis, have been described in NVG patients [4–5].

Platelets play an important role in the pathogenesis of various thrombo-occlusive diseases, such as anterior ischemic optic neuropathy [6], ischemic and hemorrhagic stroke [7], and RVO [8]. Mean platelet volume (MPV) is a major indicator of the production rate and size of platelets, and has been associated with the activities of platelets [9, 10]. Large platelets are more reactive in metabolic and enzymatic activity than small platelets, and aggregate more easily than the latter [11, 12]. Platelet count reflects the production and aging of platelets, and is also an important platelet parameter [13, 14]. Two other platelet parameters are the plateletcrit (PCT) and the platelet distribution width (PDW), representing the fraction of platelets in blood and the variation in size of platelets, respectively [15, 16]. Yazgan S et al [17] suggested that the PCT and PDW were significantly higher in patients with PEX syndrome than in controls. Sahin A et al [8] reported that patients with RVO had significantly higher MPV values compared with the control subjects. Aksoy Y et al [18] also suggested that MPV values were significantly higher in branch RVO patients compared with the control subjects. However, inconsistent results showing that the MPV was significantly lower in patients with RVO than a control group were reported by Ornek N et al [19]. Moreover, to our knowledge, we did not find any articles that assessed platelet parameters in patients with NVG secondary to DR and RVO.

Several studies have shown that DR has higher MPV than healthy controls, which indicated that increased MPV may be a risk factor of retinopathy in DM patients [20, 21]. Citirik et al [22] reported that DR patients have a higher MPV than diabetic patients without DR. However, there are currently no reports on whether platelet parameters differ between DM patients and patients with NVG secondary to DR. Therefore, the aim of this study was to compare platelet parameters (platelet count, MPV, PCT and PDW) in patients with NVG with either RVO or DR, in comparison to DM and control subjects.

**Materials and Methods**

**Patients**

This was a retrospective, case-control study design. The study was approved by the Ethics Committee of the Eye-ENT Hospital of Fudan University, Shanghai, China and was conducted according to the Declaration of Helsinki. Written informed consent for the use of any clinical
data in research was obtained for all patients at the time of admission to the Eye-ENT Hospital of Fudan University. Subjects, including those with NVG secondary to RVO and those secondary to DR, were recruited from the department of ophthalmology inpatient service at Eye-ENT Hospital of Fudan University from January 2012 to December 2015. Normal controls and DM patients were recruited from people through annual health screenings.

Inclusion criteria

The diagnosis of NVG was made at the Eye-ENT Hospital of Fudan University. The definition of NVG was: (1) IOP > 21 mmHg; (2) caused by retinal vascular disease (RVO or DR); (3) the presence of active neovascularization in the iris and/or angle; (4) with or without antiglaucomatous medications. [23] Newly diagnosed NVG patients and referral NVG patients were also included. Each patient underwent a standardized ophthalmic examination, which included refractive status, slit-lamp biomicroscopy, fundus examination, IOP (intraocular pressure), CCT (central corneal thickness), AL (axial length), ACD (anterior chamber depth), visual field examination, and gonioscopy, performed by glaucoma specialists. The MD and MS were measured by Octopus automated perimetry (HAAG, STREIT, Switzerland). A visual acuity measurement was obtained for each patient based on the International Standard Visual Acuity Chart. IOP was measured using the Goldmann applanation tonometry. Fundus photography was performed with a retinal camera (TRC-NW200, Topcon). A-scan ultrasound (A-Scan Pachymeter, Ultrasonic, Exton, PA, USA) was used to measure AL, ACD, and CCT. Patients with any systemic disease other than hypertension and diabetes mellitus were excluded from the study [8].

The NVG patients were divided into 2 categories for analysis: patients with open angle and high IOP (>21 mmHg) due to neovascularization (O-NVG group); and patients with closed angle and high IOP (>21 mmHg) (C-NVG group). [24, 25]

Normal controls had no ocular diseases, or systemic diseases such as diabetes, cardiovascular disease, anemia, autoimmune disease, cancer, and acute infectious disease. DM patients were excluded if they had any retinopathy or any other ocular diseases, as well as any systemic diseases such as cardiovascular disease, anemia, autoimmune disease, cancer, and acute infectious disease.

Platelet parameters

Platelet parameters were measured with the Mindray BC-5500 (Shenzhen, China) automatic blood counting system. All blood samples in our study were collected in ethylenediaminetetraacetic acid (EDTA) tubes.

Data analysis

The data were analyzed by SPSS13.0 (SPSS Inc., Chicago, IL). Results are presented as mean ± standard deviation (SD). Normality was assessed with the Kolmogorov-Smirnoff test. Chi-square test and Fisher exact tests were used for categorical variables. Baseline demographic information and clinical ocular parameters were compared between groups using the independent sample t test or one-way ANOVA test. The one-way ANOVA test was used to compare the levels of platelet parameters among the three groups. Multiple logistic regression analyses were performed to identify platelet risk factors associated with NVG patients with RVO or DR, compared to the control subjects. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated using logistic regression models. A P value of less than 0.05 was considered statistically significant.
Results

Characteristics of the study patients

A total of 38 NVG secondary to RVO patients (RVO group), 47 NVG secondary to DR patients (RVO group), 52 DM patients and 48 control subjects were enrolled in this study. Only one eye was selected randomly if both eyes suffered from NVG. The RVO group, DR group and control group were closely matched in terms of mean age and gender (p = 0.762, p = 0.736, respectively). No significant differences among the 3 groups were observed regarding any of the demographic and clinical ocular characteristics, except for diabetes mellitus (Table 1).

Comparison of PLT PDW, PCT, and MPV in RVO, DR, and control group

The mean level of PDW was significantly higher (p<0.001) in the RVO group (15.16±2.13fl) and the DR group (16.17±1.66fl) when compared with the control group (13.77±2.99fl). The mean PCT value of the RVO group (0.229±0.063%) was also significantly higher (p = 0.049) than the control group (0.199±0.045). In the DR group, MPV value (10.72±1.57fl) was significantly higher (p = 0.002) than the control group (9.75±0.89fl). There was no statistical difference in the PLT among the three groups (p = 0.108) (Table 2). RVO, DR, and control group

Table 1. Demographics of the study participants by NVG secondary to RVO patients, NVG secondary to DR patients, and controls.

|                  | RVO group            | DR group            | Control group        | t value | p value |
|------------------|----------------------|---------------------|----------------------|---------|---------|
| Age (years)      | 56.32±15.41          | 54.09±10.75         | 55.08±15.23          | 0.272   | 0.762   |
| Gender (male/female) | 24/14               | 26/21               | 27/21                | 0.613   | 0.736   |
| Diabetes mellitus| 4 (10.53%)           | 47 (100%)           | 0 (0%)               | 142.116 | <0.001  |
| BMI, Kg/m²       | 23.99±3.71           | 22.72±3.47          | 24.80±4.19           | 1.818   | 0.171   |
| Hypertension     | 22 (57.89%)          | 23 (48.94%)         | 20 (41.67%)          | 2.235   | 0.327   |
| IOP (mmHg)       | 42.92±11.76          | 38.89±13.46         | -                    | 1.338   | 0.185   |
| VCDR             | 0.65±0.24            | 0.59±0.19           | -                    | 0.899   | 0.375   |
| MD (dB)          | 23.36±6.45           | 25.89±1.67          | -                    | 1.423   | 0.176   |
| MS (dB)          | 4.51±6.76            | 1.78±1.45           | -                    | 1.478   | 0.161   |
| Visual acuity    | 0.31±0.13            | 0.28±0.11           | -                    | 1.021   | 0.310   |

Data are expressed as mean± standard deviation (SD). Chi-square test, Fisher exact tests, independent sample t test and One-way ANOVA was used. BMI: body mass index, IOP: intraocular pressure, VCDR: vertical cup-disc ratio, MD: visual fields mean deviation, MS: visual fields mean sensitivity. RVO: neovascular glaucoma secondary to retinal vein occlusion. DR: neovascular glaucoma secondary to diabetic retinopathy.

doi:10.1371/journal.pone.0166893.t001

Table 2. Laboratory findings that PLT, PDW, PCT, and MPV in RVO, DR, and control group.

|                  | RVO group (n = 38) | DR group (n = 47) | Control group (n = 48) | t value | p value |
|------------------|--------------------|-------------------|------------------------|---------|---------|
| PLT (10⁹/l)      | 228.71±72.11       | 205.43±60.55      | 202.06±53.08           | 2.267   | 0.108   |
| PDW (fl)         | 15.16±2.13         | 16.17±1.66        | 13.77±2.99             | 12.533  | <0.001ᵃᵇ |
| PCT (%)          | 0.229±0.063        | 0.218±0.058       | 0.199±0.045            | 3.076   | 0.049ᵃ   |
| MPV (fl)         | 10.20±1.44         | 10.72±1.57        | 9.75±0.89              | 6.297   | 0.002ᵇ   |

Data are expressed as mean± standard deviation (SD). One-way ANOVA was used. RVO: neovascular glaucoma secondary to retinal vein occlusion. DR: neovascular glaucoma secondary to diabetic retinopathy. MPV: mean platelet volume. PDW: platelet distribution width. PCT: plateletcrit. PLT: platelet count.

ᵃp<0.05 for the difference between RVO group and Control group (1-way ANOVA with the LSD post hoc test).
ᵇp<0.05 for the difference between DR group and Control group (1-way ANOVA with the LSD post hoc test).
ᶜp<0.05 for the difference between RVO group and DR group (1-way ANOVA with the LSD post hoc test).

doi:10.1371/journal.pone.0166893.t002
were categorized as 3 subgroups (20–39 years, 40–59 years, and 60+ years) based on age. A similar trend was observed when PDW, PCT, and MPV were compared among the 3 subgroups (Table 3). However, among the RVO, DR, and control group aged 40–59 years, PDW level did not differ significantly ($p = 0.208$). Among patients aged 20–39 years and 60+ years, PCT level did not differ significantly ($p = 0.484$, $p = 0.052$, respectively). Among patients aged 40–59 years, the MPV level was not statistically different ($p = 0.270$).

Comparison of platelet parameters and demographics in O-NVG and C-NVG group

The NVG patients were divided into 2 categories for analysis: O-NVG group (n = 29) and C-NVG group (n = 56). Because the NVG was defined as IOP $> 21$ mmHg in this study, patients with simply iris neovascularization (without IOP elevation) was lacking. No significant differences between the O-NVG group and C-NVG group were observed in terms of the demographic and platelet parameters, except for hypertension (Table 4). The C-NVG group has a higher level of VCDR and MD than the O-NVG group ($p = 0.005$, $p = 0.005$, respectively). Moreover, the level of MS and visual acuity was higher in the O-NVG group than the C-NVG group ($p = 0.010$, $p = 0.014$, respectively).

Comparison of PLT PDW, PCT, and MPV in DM, DR, and control group

No significant differences among the DM (diabetics mellitus without retinopathy), DR (patients with NVG secondary to DR), and control groups were observed regarding any of the demographic (Table 5). The DM group, DR group, and control group were closely matched in terms of mean age and gender. The mean level of PDW was significantly higher ($p < 0.001$) in the DR group (16.17±1.66fl) compared to the DM group (13.80±3.32fl) and the control group (13.77±2.99fl). However, PDW level did not differ significantly between the DM group and control group. The mean level of MPV was significantly higher ($p < 0.001$) in the DM group (10.39±0.90fl) and DR group (10.72±1.57fl) compared to the control group (9.75±0.89fl). The

| Table 3. Comparison of PDW, PCT, and MPV in RVO, DR, and control group, by age. |
|---------------------------------|-----------------|-----------------|-----------|--------|--------|
|                                 | RVO group (n = 38) | DR group (n = 47) | Control group (n = 48) | t value | p value |
| PDW (fl)                        |                  |                  |                      |        |
| 20–39 years                     | 14.13±3.06 (n = 6) | 16.67±0.54 (n = 7) | 14.12±2.98 (n = 12) | 3.076  | 0.049$^b$|
| 40–59 years                     | 15.50±1.71 (n = 16) | 15.76±2.18 (n = 25) | 14.49±2.80 (n = 16) | 1.615  | 0.208  |
| 60+ years                       | 15.21±2.13 (n = 16) | 16.61±0.25 (n = 15) | 12.99±3.10 (n = 20) | 11.141 | <0.001$^{a,b}$ |
| PCT (%)                         |                  |                  |                      |        |
| 20–39 years                     | 0.20±0.063 (n = 6) | 0.23±0.052 (n = 7) | 0.21±0.050 (n = 12) | 0.749  | 0.484  |
| 40–59 years                     | 0.24±0.043 (n = 16) | 0.23±0.059 (n = 25) | 0.20±0.036 (n = 16) | 3.416  | 0.040$^{a,b}$ |
| 60+ years                       | 0.22±0.077 (n = 16) | 0.17±0.039 (n = 15) | 0.18±0.049 (n = 20) | 3.145  | 0.052  |
| MPV (fl)                        |                  |                  |                      |        |
| 20–39 years                     | 9.78±1.05 (n = 6) | 11.67±1.48 (n = 7) | 10.03±0.82 (n = 12) | 6.457  | 0.006$^{b,c}$ |
| 40–59 years                     | 10.22±1.37 (n = 16) | 10.56±1.71 (n = 25) | 9.81±0.89 (n = 16) | 1.342  | 0.270  |
| 60+ years                       | 10.34±1.67 (n = 16) | 10.53±1.27 (n = 15) | 9.55±0.93 (n = 20) | 3.765  | 0.030$^{b}$ |

Data are expressed as mean± standard deviation (SD). One-way ANOVA was used. RVO: neovascular glaucoma secondary to retinal vein occlusion. DR: neovascular glaucoma secondary to diabetic retinopathy. MPV: mean platelet volume. PDW: platelet distribution width. PCT: plateletcrit.

$^a$P<0.05 for the difference between RVO group and Control group (1-way ANOVA with the LSD post hoc test).
$^b$P<0.05 for the difference between DR group and Control group (1-way ANOVA with the LSD post hoc test).
$^c$P<0.05 for the difference between RVO group and DR group (1-way ANOVA with the LSD post hoc test).

doi:10.1371/journal.pone.0166893.t003

were categorized as 3 subgroups (20–39 years, 40–59 years, and 60+ years) based on age. A similar trend was observed when PDW, PCT, and MPV were compared among the 3 subgroups (Table 3). However, among the RVO, DR, and control group aged 40–59 years, PDW level did not differ significantly ($p = 0.208$). Among patients aged 20–39 years and 60+ years, PCT level did not differ significantly ($p = 0.484$, $p = 0.052$, respectively). Among patients aged 40–59 years, the MPV level was not statistically different ($p = 0.270$).
DR group has a higher level of MPV than the DM group, but this was not statistically different. There was no statistical difference in the PLT and PCT among the three groups (Table 5).

The association of PDW, PCT, and MPV with RVO, DR, and control individuals by multiple logistic regression analysis

Stepwise multiple logistic regression analysis revealed that PDW (OR = 1.44, 95%CI = 1.149–1.805, \(p = 0.002\)) and MPV (OR = 1.503, 95%CI = 1.031–2.192, \(p = 0.034\)) were associated with DR after adjusting for age, sex, PLT, PDW, PCT, MPV, and hypertension (Table 6). PDW (OR = 1.207, 95%CI = 1.010–1.443, \(p = 0.003\)) and PCT (OR = 1.663, 95%CI = 1.870–2.654, \(p = 0.003\)) were associated with DR after adjusting for age, sex, PLT, PDW, PCT, MPV, and hypertension (Table 6). PDW (OR = 1.207, 95%CI = 1.010–1.443, \(p = 0.003\)) and PCT (OR = 1.663, 95%CI = 1.870–2.654, \(p = 0.003\)) were associated with DR after adjusting for age, sex, PLT, PDW, PCT, MPV, and hypertension (Table 6).

Table 4. Comparison of platelet parameters and demographics in O-NVG and C-NVG group.

|                      | O-NVG group (n = 29) | C-NVG group (n = 56) | t value | p value |
|----------------------|----------------------|----------------------|---------|---------|
| Age (years)          | 54.17±11.15          | 55.55±13.92          | 0.462   | 0.645   |
| Gender (male/female) | 17/12                | 33/23                | 0.001   | 0.978   |
| Diabetes mellitus    | 17 (58.62%)          | 34 (60.715)          | 0.035   | 0.852   |
| Hypertension         | 5 (17.24%)           | 40 (71.43%)          | 22.518  | <0.001  |
| BMI, Kg/m²           | 22.51±3.27           | 22.02±7.25           | 0.279   | 0.781   |
| PLT (10⁹/l)          | 213.86±70.06         | 216.86±65.34         | 0.195   | 0.845   |
| PDW (fl)             | 15.59±2.04           | 15.79±1.89           | 0.433   | 0.666   |
| PCT (%)              | 0.221±0.057          | 0.224±0.062          | 0.222   | 0.825   |
| MPV (fl)             | 10.65±1.73           | 10.40±1.42           | 0.704   | 0.483   |
| IOP (mmHg)           | 43.41±10.39          | 41.11±14.62          | 0.749   | 0.456   |
| VCDR                 | 0.51±0.17            | 0.70±0.20            | 3.004   | 0.005   |
| MD (dB)              | 20.78±5.87           | 27.04±0.94           | 3.508   | 0.005   |
| MS (dB)              | 6.90±6.36            | 0.77±1.00            | 3.174   | 0.010   |
| Visual acuity        | 0.33±0.11            | 0.27±0.12            | 2.521   | 0.014   |

Data are expressed as mean± standard deviation (SD). Chi-square test and independent sample t test was used. O-NVG: open angle and high IOP (>21mmHg) due to neovascularization, C-NVG: closed angle and high IOP (>21mmHg) due to neovascularization, BMI: body mass index, IOP: intraocular pressure, VCDR: vertical cup-disc ratio, MD: visual fields mean deviation, MS: visual fields mean sensitivity. MPV: mean platelet volume. PDW: platelet distribution width. PCT: plateletcrit. PLT: platelet count.

doi:10.1371/journal.pone.0166893.t004

Table 5. Laboratory findings that PLT, PDW, PCT, and MPV in DM, DR, and control group.

|                      | DM group | DR group | Control group | t value | p value |
|----------------------|----------|----------|---------------|---------|---------|
| Age (years)          | 55.08±15.23 | 54.09±10.75 | 55.08±15.23 | 0.077   | 0.926   |
| Gender (male/female) | 31/21    | 26/21    | 27/21         | 0.209   | 0.901   |
| Diabetes mellitus    | 52 (100%) | 47 (100%) | 0 (0%)        | 147.00  | <0.001  |
| Hypertension         | 25 (48.8%)| 23 (48.94%)| 20 (41.67%)  | 0.612   | 0.736   |
| PLT (10⁹/l)          | 205.33±86.02 | 205.43±60.55 | 202.06±53.08 | 0.038   | 0.963   |
| PDW (fl)             | 13.80±3.32 | 16.17±1.66 | 13.77±2.99   | 11.786  | <0.001  |
| PCT (%)              | 0.214±0.066 | 0.218±0.058 | 0.199±0.045 | 1.630   | 0.200   |
| MPV (fl)             | 10.39±0.90 | 10.72±1.57 | 9.75±0.89    | 8.433   | <0.001  |

Data are expressed as mean± standard deviation (SD). One-way ANOVA was used. DM: diabetes mellitus without retinopathy. DR: neovascular glaucoma secondary to diabetic retinopathy. MPV: mean platelet volume. PDW: platelet distribution width. PCT: plateletcrit. PLT: platelet count.

\(aP<0.05\) for the difference between DM group and Control group (1-way ANOVA with the LSD post hoc test).

\(bP<0.05\) for the difference between DM group and Control group (1-way ANOVA with the LSD post hoc test).

\(cP<0.05\) for the difference between DR group and Control group (1-way ANOVA with the LSD post hoc test).

doi:10.1371/journal.pone.0166893.t005
p = 0.036) were associated with RVO after adjusting for age, sex, PLT, PDW, PCT, MPV, and hypertension (Table 7).

**Discussion**

Retinal ischemia and macular oedema arising from RVO and DR are the most common cause of vision loss [26]. The exact mechanism of NVG secondary to RVO or DR is multifactorial and remains unknown. It has been shown that platelets play an important role in the pathophysiology of retinal artery occlusion [27], nonarteritic anterior ischemic optic neuropathy [6], ischemic and hemorrhagic stroke [7], and cardiovascular diseases [28]. In this study, 38 patients with NVG secondary to RVO and 47 patients with NVG secondary to DR were studied with regard to platelet parameters and compared to control subjects. Moreover, 47 patients with NVG secondary to DR were studied with regard to platelet parameters and compared to DM patients without retinopathy.

The main finding in the present study was that PDW and PCT were higher in patients with NVG secondary to RVO than in the control group and associated with higher prevalence of NVG secondary to RVO according to multiple logistic regression analysis. Furthermore, the levels of PDW and MPV in patients in the NVG secondary to DR group were higher than in the control group. Multiple logistic regression analysis revealed a significant association between PDW and MPV with NVG secondary to DR. The above association remained significant even after adjustment for age, sex, PLT, PDW, PCT, MPV, and hypertension. Our results suggest that platelet function might be an important factor in the onset and/or development of NVG. Furthermore, we found that the mean level of PDW was significantly higher in the NVG secondary to DR group compared with the DM group.

There has been a few studies which have evaluated the relationship between MPV and cardiovascular disease [27, 29–31]. Sahin M et al [27] reported that patients with retinal artery occlusion had significantly higher MPV values compared with control subjects and was an independent predictor of retinal artery occlusion. MPV as risk factors has been studied in patients with deep vein thrombosis. Han JS et al [31] reported that median MPV was higher in deep vein thrombosis patients and could be considered as a meaningful laboratory marker for deep vein thrombosis. In addition, MPV is elevated in sinus thrombosis [32] and pulmonary

| Risk factors | Odds Ratio | 95% Confidence Interval | p value * |
|--------------|------------|-------------------------|-----------|
| PDW (fl)     | 1.44       | 1.149–1.805             | 0.002     |
| MPV (fl)     | 1.503      | 1.031–2.192             | 0.034     |

* Adjusted for age, sex, platelet count, platelet distribution width, plateletcrit, mean platelet volume, hypertension. MPV: mean platelet volume. PDW: platelet distribution width.

doi:10.1371/journal.pone.0166893.t006

| Risk factors | Odds Ratio | 95% Confidence Interval | p value * |
|--------------|------------|-------------------------|-----------|
| PDW (fl)     | 1.207      | 1.010–1.443             | 0.039     |
| PCT (%)      | 1.663      | 1.870–2.654             | 0.003     |

* Adjusted for age, sex, platelet count, platelet distribution width, plateletcrit, mean platelet volume, hypertension. PDW: platelet distribution width. PCT: plateletcrit

doi:10.1371/journal.pone.0166893.t007
thromboembolism [33]. These studies suggest that a higher MPV was a risk factor for thrombogenesis.

In our study, the MPV values were significantly higher in patients with NVG secondary to DR and associated with higher prevalence of NVG secondary to DR according to multiple logistic regression analysis. Citirik et al [22] also found that DR patients have increased MPV values compared with healthy subjects, and similar results were reported by another study [34]. Therefore, a higher MPV seems to be a risk factor for DR. In our study, the MPV values in RVO patients were also higher than in the control group but not statistically significant. However, a few studies reported that the MPV values were significantly higher in patients with RVO [18, 35], and inconsistent results were also reported where the MPV was significantly lower in patients with RVO than the control group [19]. Therefore, we expect future studies to confirm the relationship between MPV and patients with NVG secondary to RVO.

PDW is another important parameter reflecting platelet function. PDW represents the variation in size of platelets and PDW has been investigated as a marker of platelet activation [16, 36]. A higher PDW has been previously observed in patients with coronary artery disease and myeloproliferative disorders [37, 38]. We found that PDW were higher in patients with NVG secondary to RVO and DR than in the control group and associated with higher prevalence of NVG according to multiple logistic regression analysis. PDW was also significantly increased in cerebral venous sinus thrombosis and might be associated with the severity of cerebral venous sinus thrombosis [32]. To our knowledge, there was only one study that explored the relationship between PDW and DR, but DR patients have no different PDW values compared with healthy subjects [22]. No study has examined the relationship between PDW and patients with NVG secondary to RVO. Therefore, this is the first study to report that PDW was higher in patients with NVG secondary to RVO and DR and suggests that increased PDW may be related to NVG.

PCT is the percentage of platelet mass in the blood and is regarded as an indicator of circulating platelets in a unit volume of blood [34]. Several studies have reported that a higher PCT level was associated with cardiovascular disease such as slow coronary flow [39], coronary artery disease [40, 41]. However, no study has investigated the relationship between PCT and NVG secondary to RVO. Akpinar I et al [39] reported that PCT level was higher in slow coronary flow patients than those without slow coronary flow. Ugur M et al [40] found that with high PCT values, cardiovascular patients had a worse prognosis. In the present study, PCT value in patients with NVG secondary to RVO was significantly higher than the control group. In addition, PCT was a risk factor of NVG secondary to RVO on the basis of a multiple logistic regression analysis adjusted for age, sex, PLT, PDW, MPV, and hypertension. This suggests that a higher PCT might be a risk factor of thrombogenesis in patients with NVG secondary to RVO.

In our study, we found that the mean level of PDW was significantly higher in patients with NVG secondary to DR group compared with the DM group. MPV was also higher in the NVG secondary to DR group than the DM group, although this difference was not statistically significant. PDW and MPV are increased during platelet activation, and this can increase the chance of vascular complications [41]. Papanas et al [42] reported that patients with DR have higher MPV levels compared with other diabetic patients. Jindal et al [16] showed that PDW levels were significantly higher in diabetic patients and the level of PDW is increased more significantly in patients with microvascular complications. However, Citirik et al [22] found that DM patients have significantly higher MPV and PDW values compared to healthy subjects, but MPV and PDW levels were not altered along with the DR stage. We thought that the following factors might explain this observation: (1) the elapsed time of MPV measurement may be different, in this study the blood was studied within 30 minutes; (2) the subjects of the
above studies differed from our study, this study investigated NVG secondary to DR, whereas
the above study explored DR or DM patients only. To the best of our knowledge, this is the
first study to explore whether platelet parameters differ between DM and NVG (secondary to
DR).

Our study did have some limitations. (1) The sample size is relatively small. A number of
patients were subsequently excluded due to the strict inclusion criteria; and to our knowledge,
this is the first study examining platelet parameters within NVG secondary to RVO and DR
patients. (2) Our study was a single-center, retrospective analysis. The results might be affected
by confounding factors, despite a multiple logistic regression analysis was performed to adjust
for age, sex, PLT, PDW, MPV, and hypertension. Therefore, larger-scale, multi-center pro-
spective studies are required to better investigate the relationship between platelets with RVO
and DR patients.

In conclusion, our results suggested that increased PDW and MPV are associated with
NVG secondary to DR, and elevated PDW and PCT increases the risk for NVG secondary to
RVO. Moreover, the mean level of PDW was significantly higher in the NVG secondary to DR
group when compared with the DM group. Platelets may not be the primary cause of NVG
with RVO or DR but may be a secondary factor that could increase the prevalence of NVG,
because platelet parameters values were still within the reference range.

Acknowledgments
This research project was supported by the Funds for International Cooperation and Exchange
of the National Natural Science Foundation of China (81020108017), the National Health and
Family Planning Commission, China(201302015), the National Major Scientific Equipment pro-
gram, the Ministry of Science and Technology, China (2012YQ12008003), the State Key Program
of National Natural Science Foundation of China (81430007), and the New Technology Research
Project, Shanghai Municipal Commission of Health and Family Planning (2013SY058). The
sponsor or funding organization had no role in the design or conduct of this research.

Author Contributions
Conceptualization: SL WC XS.
Data curation: SL.
Formal analysis: SL.
Funding acquisition: WC XS.
Investigation: SL.
Methodology: SL WC XS.
Project administration: WC XS.
Resources: SL WC XS.
Software: SL.
Supervision: WC XS.
Validation: SL WC XS.
Writing – original draft: SL.
Writing – review & editing: SL WC XS.
References

1. Aaberg TM. Pars plana vitrectomy for diabetic traction retinal detachment. Ophthalmology. 1981; 88:639–642. PMID: 7267031

2. Beer PM, Wong SJ, Hammad AM, Falk NS, O’Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006; 26:671–676. doi: 10.1097/iae.0000233237.69433.02 PMID: 17051985

3. Chen S, Zhou M, Wang W, Wu H, Yu X, Huang W, et al. Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes. Acta Ophthalmol. 2015; 93:e556–e560. doi: 10.1111/aos.12624 PMID: 25783445

4. Leoncini G, Bruzzese D, Signorrollo MG, Armani U, Piana A, Ghiglione D, et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost. 2007; 97:218–227. PMID: 17264950

5. Yoshizumi MO, Townsend-Pico W. Essential thrombocytemia and central retinal vein occlusion with neovascular glaucoma. Am J Ophthalmol. 1996; 121:728–730. PMID: 8644826

6. Sahin M, Sahin A, Elbey B, Yuksel H, Turkcu FM, Cingu AK. Mean Platelet Volume in Patients with Nonarteritic Anterior Ischemic Optic Neuropathy. J Ophthalmol. 2016; 2016:1051572. doi: 10.1155/2016/1051572 PMID: 26966556

7. Du J, Wang Q, He B, Liu P, Chen JY, Quan H, et al. Association of mean platelet volume and platelet count with the development and prognosis of ischemic and hemorrhagic stroke. Int J Lab Hematol.2016; 38: 233–239. doi: 10.1111/jlh.12474 PMID: 26992440

8. Sahin A, Sahin M, Yuksel H, Turkcu FM, Cinar Y, Cingu AK, et al. The mean platelet volume in patients with retinal vein occlusion. J Ophthalmol.2013. 2013: 236371. doi: 10.1155/2013/236371 PMID: 23781328

9. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002; 13:301–306. doi: 10.1080/095371002220148332 PMID: 12189016

10. Vagdatli E, Gounari E, Lazaridou E, Katsbourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010; 14:28–32. PMID: 20411056

11. Ulu S, Ulu MS, Ahsen A, Yucedag F, Ayicek A, Celik S. Increased levels of mean platelet volume: a possible relationship with idiopathic sudden hearing loss. Eur Arch Otorhinolaryngol. 2013; 270:2875–2878. doi: 10.1007/s00405-013-2348-9 PMID: 23341093

12. Haver VM, Gear AR. Functional fractionation of platelets. J Lab Clin Med. 1981; 97:187–204. PMID: 7450290

13. Daly ME. Determinants of platelet count in humans. Haematologica. 2011; 96:10–13. doi: 10.3324/haematol.2010.035287 PMID: 21193429

14. Latorre R, Vaquero J, Rincon D, Puerto M, Ponce MD, Sarnago F, et al. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver Int. 2016; 36:232–239. doi: 10.1111/liv.12908 PMID: 26134264

15. Tvedten H, Lilliehook I, Hillstrom A, Haggstrom J. Plateletcrit is superior to platelet count for assessing platelet status in Cavalier King Charles Spaniels. Vet Clin Pathol. 2008; 37:266–271. doi: 10.1111/j.1939-165X.2008.00054.x PMID: 18761517

16. Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, et al. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 2011; 16:86–89. doi: 10.1179/102453311X12902908412110 PMID: 21418738

17. Yazgan S, Celik U, Kaldrm H, Ayar O, Akdemir MO. Plateletcrit in Ocular Pseudoexfoliation Syndrome. Eye Contact Lenses. 2016; 42:328–332. doi: 10.1097/ICL.0000000000000197 PMID: 26448448

18. Aksoy Y, Eyi YE, Kar T, Sevinc MK. Mean platelet volume as a marker of branch retinal vein occlusion may be influenced by many factors. Indian J Ophthalmol. 2013; 61:686–687. doi: 10.4103/0301-4738.119414 PMID: 24145568

19. Ornek N, Ogurel T, Ornek K, Onaran Z. Mean platelet volume in retinal vein occlusion. Eur Rev Med Pharmacol Sci. 2014; 18:2778–2782. PMID: 25339469

20. Ates O, Kiki I, Bilen H, Keles M, Kocer I, Kulacoglu DN, et al. Association of mean platelet volume with the degree of retinopathy in patients with diabetes mellitus. Eur J Gen Med. 2009; 6: 99–102.

21. Ayhan TE, Arica S, Ilhan N, Daglioglu M, Coskun M, Ilhan O, et al. Relationship between mean platelet volume and retinopathy in patients with type 2 diabetes mellitus. Graefes Arch Clin Exp Ophthal- mol.2014; 252:237–240. doi: 10.1007/s00417-013-2444-y PMID: 23955724

22. Citrik M, Beyazylidiz E, Simsek M, Beyazylidiz O, Haznedaroğlu IC. MPV may reflect subclinical platelet activation in diabetic patients with and without diabetic retinopathy. Eye (Lond). 2015; 29:376–379.
23. Higashide T, Ohkubo S, Sugiyama K. Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma. PLOS ONE. 2015; 10: e135766.

24. Nakano S, Nakamura T, Yokoyama K, Kiyosaki K, Kubota T. Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma. J OPHTHALMOL. 2016; 2016:1205895. doi: 10.1155/2016/1205895 PMID: 26777606

25. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115: 1571–1581. doi: 10.1016/j.ophtha.2008.02.026 PMID: 18440643

26. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol. 1993; 111:1087–1095. PMID: 7688950

27. Sahin M, Sahin A, Yuksel H, Turkcu FM, Yildirim A. Mean platelet volume in patients with retinal artery occlusion. Arq Bras Oftalmol. 2016; 79:12–14. doi: 10.5935/0004-2749.20160005 PMID: 26840159

28. Sansanayudh N, Munthon D, Yamwong S, Sritara P, Akrawichien T, Thakkinstian A. The association between mean platelet volume and cardiovascular risk factors. EUR J INTERN MED. 2016; 30:37–42. doi: 10.1016/j.ejim.2015.11.028 PMID: 27579175

29. O’Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke. 1995; 26:995–999. PMID: 7762052

30. Erne P, Wardle J, Sanders K, Lewis SM, Maseri A. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost. 1988; 59:259–263. PMID: 3382897

31. Han JS, Park TS, Cho SY, Joh JH, Ahn HJ. Increased mean platelet volume and mean platelet volume/platelet count ratio in Korean patients with deep vein thrombosis. Platelets. 2013; 24:590–593. doi: 10.3109/09537104.2012.748187 PMID: 23215785

32. Kamisi O, Kamisli S, Kablan Y, Gonullu S, Ozcan C. The prognostic value of an increased mean platelet volume and platelet distribution width in the early phase of cerebral venous sinus thrombosis. Clin Appl Thromb Hemost. 2013; 19:29–32. doi: 10.1177/1076029612453196 PMID: 22815317

33. Varol E, Icli A, Uysal BA, Ozaydin M. Platelet indices in patients with acute pulmonary embolism. Scand J Clin Lab Invest. 2011; 71:163–167. doi: 10.3109/00365513.2010.547596 PMID: 21208032

34. Zhong ZL, Han M, Chen S. Risk factors associated with retinal neovascularization of diabetic retinopathy in type 2 diabetes mellitus. Int J Ophthalmol. 2011; 4:182–185. doi: 10.3980/j.issn.2222-3959.2011.02.15 PMID: 22553638

35. Onder HI, Kilic AC, Kaya M, Bulur S, Onder E, Tunc M. Relation between platelet indices and branch retinal vein occlusion in hypertensive patients. Indian J Ophthalmol. 2013; 61:160–162. doi: 10.4103/0301-4738.111063 PMID: 23619481

36. De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, et al. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets. 2010; 21:508–514. doi: 10.3109/09537104.2010.494743 PMID: 20874431

37. Khondekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Kadtare AD, Inamdar AK. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol. 2006; 59:146–149. doi: 10.1136/jcp.2004.025387 PMID: 16443728

38. Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem. 1997; 43:1072–1076. PMID: 9191563

39. Akpinar I, Sayin MR, Gursoy YC, Aktop Z, Karabag T, Kucuk E, et al. Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. J Cardiol. 2014; 63:112–118. doi: 10.1016/j.jcc.2013.07.010 PMID: 24012331

40. Ugur M, Ayhan E, Bozbay M, Cicek G, Ergelen M, Isik T, et al. The independent association of plateletcrit with long-term outcomes in patients undergoing primary percutaneous coronary intervention. J Crit Care. 2014; 29:978–981. doi: 10.1016/j.jcrc.2014.07.001 PMID: 25124920

41. Kodiatte TA, Manikyam UK, Rao SB, Jagadish TM, Reddy M, Lingiaah HK, et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians. 2012; 4:5–9. doi: 10.4103/0974-2727.98662 PMID: 22932915

42. Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004; 15: 475–478. doi: 10.1080/0953710042000267707 PMID: 15763888